Morning Overview on MSN
Experimental prostate cancer drug shrinks tumors in early clinical trial
Several experimental prostate cancer drugs have produced striking results in early-stage clinical trials, with at least one ...
Data from 2 studies, LIGHTHOUSE and SPOTLIGHT, have shown the benefit of flotufolastat F 18 injection as a radiohybrid PSMA-targeted PET imaging agent in prostate cancer. The agent has now been added ...
− Oral presentation highlighted at 2023 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting – MONROE TOWNSHIP, N.J. & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a ...
MONROE TOWNSHIP, NJ, & OXFORD, England--(BUSINESS WIRE)--Blue Earth Diagnostics, a Bracco company and recognized leader in the development and commercialization of innovative PET radiopharmaceuticals, ...
A new drug for prostate cancer, which delivers a precisely targeted dose of radiation to cancer cells, can keep cancer at bay, a phase I trial reports. The ‘search and destroy’ treatment shrank ...
NEW YORK (Reuters Health) - For men suffering the discomforts of an enlarged prostate, injections of Botox into the prostate may bring relief for up to 30 months, doctors in Italy report. Dr. Giuseppe ...
Detailed price information for Lantheus Holdings (LNTH-Q) from The Globe and Mail including charting and trades.
New formulation of its widely-used U.S. market-leading PSMA PET imaging agent combines thediagnostic performance of PYLARIFY (piflufolastat F 18) with the potential for larger batches and greater pati ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results